Abstract
Multiple myeloma (MM) is a complex disease driven by numerous genetic and epigenetic alterations that are acquired over time. Despite recent progress in the understanding of MM pathobiology and the availability of innovative drugs, which have pronounced clinical outcome, this malignancy eventually progresses to a drug-resistant lethal stage and, thus, novel therapeutic drugs/models always play an important role in effective management of MM. Modulation of tumor microenvironment is one of the hallmarks of cancer biology, including MM, which affects the myeloma genomic architecture and disease progression subtly through chromatin modifications. The bone marrow niche has a prime role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the ecosystem between multiple myeloma bone marrow microenvironment and chromatin remodeling. Extensive gene expression profile analysis has indeed provided the framework for new risk stratification of MM patients and identifying novel molecular targets and therapeutics. However, key tumor microenvironment factors/immune cells and their interactions with chromatin remodeling complex proteins that drive MM cell growth and progression remain grossly undefined.
Reference136 articles.
1. Multiple myeloma;Kumar;Nat. Rev. Dis. Primers,2017
2. Multiple myeloma epidemiology and survival: A unique malignancy;Kazandjian;Semin. Oncol.,2016
3. Manojlovic, Z., Christofferson, A., Liang, W.S., Aldrich, J., Washington, M., Wong, S., Rohrer, D., Jewell, S., Kittles, R.A., and Derome, M. (2017). Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet., 13.
4. ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells;Yamamoto;Nat. Chem. Biol.,2020
5. Epigenetics in cancer: Targeting chromatin modifications;Ellis;Mol. Cancer Ther.,2009
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献